Ian Edvalson is a highly respected life sciences and technology transactions attorney with more than 30 years of combined legal and business experience advising many of the world’s leading biotechnology, pharmaceutical, medical technology, diagnostics, and life sciences companies on complex strategic transactions, commercialization initiatives, and high value corporate partnerships. He is a partner in the life sciences commercial and technology transactions practice at Wilson Sonsini Goodrich & Rosati, one of the world’s premier law firms serving the technology, venture capital, healthcare, and life sciences industries.

Based in the firm’s Palo Alto office and formerly a member of Wilson Sonsini’s Board of Directors, Ian advises both public and private companies throughout the United States and internationally on sophisticated transactions supporting the discovery, development, manufacturing, supply, licensing, and commercialization of pharmaceutical products, medical technologies, diagnostics, genomics platforms, and advanced healthcare technologies.

Ian is particularly recognized for his extensive expertise structuring and negotiating complex strategic alliances, licensing arrangements, co-development collaborations, research agreements, commercialization partnerships, joint ventures, supply agreements, manufacturing arrangements, and asset acquisitions involving high value pharmaceutical, biotechnology, and healthcare assets. His work frequently involves mission critical transactions central to product development, pipeline expansion, intellectual property monetization, financing strategy, and long term corporate growth.

Over the course of his career, Ian has represented leading biotechnology, pharmaceutical, diagnostics, genomics, and medtech companies in transactions involving billions of dollars in aggregate strategic value. He regularly counsels executive teams, boards of directors, founders, and investors on maximizing the commercial and strategic value of intellectual property portfolios, product pipelines, platform technologies, and global commercialization opportunities within highly competitive and rapidly evolving healthcare markets.

Prior to his legal practice, Ian also held executive business leadership roles within the biotechnology sector, including responsibility for corporate and business development activities at Third Wave Technologies, a publicly traded genomics and molecular diagnostics company focused on nucleic acid analysis technologies and advanced diagnostic platforms. His experience operating within a growth stage public biotechnology company provides him with a uniquely practical and commercially focused perspective when advising clients on strategic transactions, business development initiatives, and long term value creation.

Ian has earned substantial recognition within the legal industry for his work advising life sciences and technology companies. He has been consistently recognized by Chambers USA: America’s Leading Lawyers for Business across numerous editions over nearly two decades, reflecting his reputation as one of the leading attorneys in the life sciences transactions sector. He has also been recognized as a Northern California Super Lawyer for his work involving complex technology and life sciences transactions.